Bio Techne Corp Stock Current Liabilities

TECH Stock

USD 75.38 0.51 0.68%

Bio Techne Corp fundamentals help investors to digest information that contributes to Bio Techne's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Techne's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Techne stock.

Short Long Term Debt Total Total Assets

The Bio Techne's current Total Current Liabilities is estimated to increase to about 167.3 M. The Bio Techne's current Non Current Liabilities Total is estimated to increase to about 499.4 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bio Techne Corp Company Current Liabilities Analysis

Bio Techne's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Current Bio Techne Current Liabilities

54.15 M

Most of Bio Techne's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Bio Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for Bio Techne is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Current Liabilities. Since Bio Techne's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Techne's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Techne's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Good Will	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.74	0.98	0.97	0.91	0.87	0.85	0.5	0.9	-0.38	0.72	0.8	0.79	0.98	0.9	0.0	0.92	0.75	0.63	0.0	0.79	0.09	0.89	0.62
Total Stockholder Equity	0.98		0.62	0.98	0.97	0.81	0.91	0.85	0.36	0.8	-0.37	0.79	0.67	0.77	0.93	0.88	0.17	0.94	0.64	0.62	-0.04	0.68	0.11	0.89	0.68
Net Debt	0.74	0.62		0.65	0.72	0.91	0.37	0.52	0.74	0.89	-0.37	0.4	0.93	0.53	0.84	0.78	-0.46	0.59	0.78	0.51	0.12	0.89	0.15	0.65	0.35
Retained Earnings	0.98	0.98	0.65		0.94	0.84	0.91	0.79	0.5	0.85	-0.31	0.72	0.72	0.77	0.93	0.83	0.05	0.87	0.69	0.53	0.01	0.71	0.11	0.84	0.6
Net Receivables	0.97	0.97	0.72	0.94		0.85	0.82	0.79	0.43	0.84	-0.49	0.8	0.74	0.7	0.95	0.93	0.11	0.95	0.71	0.59	0.0	0.74	0.15	0.88	0.69
Total Liab	0.91	0.81	0.91	0.84	0.85		0.67	0.74	0.72	0.98	-0.35	0.47	0.96	0.74	0.95	0.84	-0.38	0.73	0.89	0.58	0.09	0.93	0.03	0.78	0.4
Total Current Assets	0.87	0.91	0.37	0.91	0.82	0.67		0.8	0.28	0.65	-0.09	0.65	0.54	0.74	0.76	0.64	0.21	0.81	0.55	0.58	-0.03	0.57	0.04	0.8	0.55
Short Term Debt	0.85	0.85	0.52	0.79	0.79	0.74	0.8		0.2	0.75	-0.25	0.47	0.58	0.89	0.82	0.82	0.06	0.86	0.61	0.77	-0.12	0.57	-0.19	0.85	0.39
Accounts Payable	0.5	0.36	0.74	0.5	0.43	0.72	0.28	0.2		0.74	-0.14	0.03	0.79	0.35	0.6	0.38	-0.69	0.19	0.73	0.04	0.35	0.74	0.27	0.31	-0.04
Intangible Assets	0.9	0.8	0.89	0.85	0.84	0.98	0.65	0.75	0.74		-0.39	0.42	0.92	0.78	0.95	0.84	-0.4	0.71	0.86	0.5	0.1	0.87	-0.03	0.75	0.35
Short Term Investments	-0.38	-0.37	-0.37	-0.31	-0.49	-0.35	-0.09	-0.25	-0.14	-0.39		-0.51	-0.32	-0.16	-0.47	-0.6	-0.12	-0.48	-0.33	-0.07	-0.01	-0.29	-0.13	-0.33	-0.48
Common Stock	0.72	0.79	0.4	0.72	0.8	0.47	0.65	0.47	0.03	0.42	-0.51		0.39	0.32	0.64	0.7	0.54	0.83	0.3	0.47	-0.11	0.43	0.35	0.7	0.91
Long Term Debt	0.8	0.67	0.93	0.72	0.74	0.96	0.54	0.58	0.79	0.92	-0.32	0.39		0.59	0.86	0.72	-0.5	0.6	0.87	0.52	0.2	0.98	0.11	0.68	0.34
Property Plant Equipment	0.79	0.77	0.53	0.77	0.7	0.74	0.74	0.89	0.35	0.78	-0.16	0.32	0.59		0.78	0.73	-0.1	0.71	0.7	0.6	-0.07	0.59	-0.29	0.81	0.39
Good Will	0.98	0.93	0.84	0.93	0.95	0.95	0.76	0.82	0.6	0.95	-0.47	0.64	0.86	0.78		0.94	-0.14	0.88	0.81	0.59	0.04	0.83	0.1	0.86	0.54
Current Deferred Revenue	0.9	0.88	0.78	0.83	0.93	0.84	0.64	0.82	0.38	0.84	-0.6	0.7	0.72	0.73	0.94		0.04	0.93	0.7	0.65	-0.04	0.7	0.08	0.88	0.62
Net Tangible Assets	0.0	0.17	-0.46	0.05	0.11	-0.38	0.21	0.06	-0.69	-0.4	-0.12	0.54	-0.5	-0.1	-0.14	0.04		0.3	-0.4	0.14	-0.29	-0.44	0.09	0.17	0.52
Capital Surpluse	0.92	0.94	0.59	0.87	0.95	0.73	0.81	0.86	0.19	0.71	-0.48	0.83	0.6	0.71	0.88	0.93	0.3		0.57	0.73	-0.12	0.61	0.13	0.92	0.74
Deferred Long Term Liab	0.75	0.64	0.78	0.69	0.71	0.89	0.55	0.61	0.73	0.86	-0.33	0.3	0.87	0.7	0.81	0.7	-0.4	0.57		0.39	0.15	0.86	-0.03	0.65	0.31
Long Term Investments	0.63	0.62	0.51	0.53	0.59	0.58	0.58	0.77	0.04	0.5	-0.07	0.47	0.52	0.6	0.59	0.65	0.14	0.73	0.39		-0.34	0.56	-0.01	0.76	0.44
Short Long Term Debt	0.0	-0.04	0.12	0.01	0.0	0.09	-0.03	-0.12	0.35	0.1	-0.01	-0.11	0.2	-0.07	0.04	-0.04	-0.29	-0.12	0.15	-0.34		0.19	0.05	0.04	-0.11
Long Term Debt Total	0.79	0.68	0.89	0.71	0.74	0.93	0.57	0.57	0.74	0.87	-0.29	0.43	0.98	0.59	0.83	0.7	-0.44	0.61	0.86	0.56	0.19		0.17	0.69	0.41
Net Invested Capital	0.09	0.11	0.15	0.11	0.15	0.03	0.04	-0.19	0.27	-0.03	-0.13	0.35	0.11	-0.29	0.1	0.08	0.09	0.13	-0.03	-0.01	0.05	0.17		-0.01	0.18
Net Working Capital	0.89	0.89	0.65	0.84	0.88	0.78	0.8	0.85	0.31	0.75	-0.33	0.7	0.68	0.81	0.86	0.88	0.17	0.92	0.65	0.76	0.04	0.69	-0.01		0.69
Capital Stock	0.62	0.68	0.35	0.6	0.69	0.4	0.55	0.39	-0.04	0.35	-0.48	0.91	0.34	0.39	0.54	0.62	0.52	0.74	0.31	0.44	-0.11	0.41	0.18	0.69

Click cells to compare fundamentals

Bio Current Liabilities Historical Pattern

Today, most investors in Bio Techne Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Techne's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bio Techne current liabilities as a starting point in their analysis.

Bio Techne Current Liabilities

Timeline

Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

Competition

Predict Bio Techne

Total Current Liabilities Over Time

Bio Total Current Liabilities

Total Current Liabilities

167.35 Million

As of now, Bio Techne's Total Current Liabilities is increasing as compared to previous years.

In accordance with the recently published financial statements, Bio Techne Corp has a Current Liabilities of 54.15 M. This is 96.91% lower than that of the Life Sciences Tools & Services sector and 90.03% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.31% higher than that of the company.

Bio Current Liabilities Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.

Bio Techne is currently under evaluation in current liabilities category among its peers.

Bio Techne ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bio Techne's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bio Techne's managers, analysts, and investors.

Environmental

Governance

Social

Bio Fundamentals

	Return On Equity	0.0729
	Return On Asset	0.0555
	Profit Margin	0.13 %
	Operating Margin	0.18 %
	Current Valuation	12.19 B
	Shares Outstanding	158.89 M
	Shares Owned By Insiders	1.03 %
	Shares Owned By Institutions	99.41 %
	Number Of Shares Shorted	3.53 M
	Price To Earning	74.38 X
	Price To Book	5.60 X
	Price To Sales	10.22 X
	Revenue	1.16 B
	Gross Profit	770.22 M
	EBITDA	310.37 M
	Net Income	168.07 M
	Cash And Equivalents	247.03 M
	Cash Per Share	6.30 X
	Total Debt	419.54 M
	Debt To Equity	0.19 %
	Current Ratio	3.44 X
	Book Value Per Share	13.46 X
	Cash Flow From Operations	298.98 M
	Short Ratio	3.43 X
	Earnings Per Share	0.95 X
	Price To Earnings To Growth	2.77 X
	Target Price	85.25
	Number Of Employees	3.1 K
	Beta	1.28
	Market Capitalization	11.98 B
	Total Asset	2.7 B
	Retained Earnings	1.33 B
	Working Capital	458.04 M
	Current Asset	253.89 M
	Current Liabilities	54.15 M
	Annual Yield	0 %
	Five Year Return	0.56 %
	Net Asset	2.7 B
	Last Dividend Paid	0.32

About Bio Techne Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:

How To Invest In Bio

Details

Is Bio Stock a good investment?

Details

What is Bio Techne's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Bio Techne Piotroski F Score and Bio Techne Altman Z Score analysis.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.32)

Dividend Share

0.32

Earnings Share

0.95

Revenue Per Share

7.424

Quarterly Revenue Growth

0.045

The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bio Techne Corp Stock Current Liabilities

Bio Techne Corp Company Current Liabilities Analysis

Current Liabilities

Payables

+

Accrued Debt

Current Bio Techne Current Liabilities

Bio Current Liabilities Driver Correlations

Bio Current Liabilities Historical Pattern

Bio Total Current Liabilities

Total Current Liabilities

167.35 Million

Bio Current Liabilities Peer Comparison

Bio Techne ESG Sustainability

Bio Fundamentals

About Bio Techne Fundamental Analysis

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY